Searchable abstracts of presentations at key conferences on calcified tissues

ba0001pp19 | Arthritis and other joint diseases: translational and clinical | ECTS2013

Vitamin K2 administration is associated with decreased disease activity in patients with rheumatoid arthritis

Ebina Kosuke , Morimoto Tokimitsu , Shi Kenrin , Kaneshiro Shoichi , Koizumi Kota , Hirao Makoto , Hashimoto Jun , Yoshikawa Hideki

Objectives: Recent studies have demonstrated that vitamin K2 (VitK2) induces apoptosis of not only osteoclasts but also rheumatoid arthritis (RA) synovial cells in vitro, while its clinical effect on disease activity of RA remains unknown.Methods: 158 female RA patients (age 62.5 years, duration of disease 14.9 years) who had not been treated with warfarin, biologics, or teriparatide were enrolled in this study. VitK2 (45 mg/day) was administered orally ...

ba0001pp258 | Chondrocytes and cartilage | ECTS2013

Transcription factor Nkx3.2 plays crucial role in primary chondrogenesis by up-regulating type II collagen a1 transcription activity

Ebina Kosuke , Kawato Yoshitaka , Hirao Makoto , Honjo Yui , Morimoto Tokimitsu , Hashimoto Jun , Shi Kenrin , Yoshikawa Hideki

Objectives: Sox9 is a dominant but insufficient transcription factor to induce thorough primary chondrogenesis, so other factors which may induce primary chondrogenesis besides Sox9 have been assumed. The previously reported function of transcription factor Nkx3.2 is to maintain chondrogenic phenotype by suppressing Runx2, while recent studies demonstrated that mouse Nkx3.2 null mice shows severe metaphyseal dysplasia which is similar to that seen in type II collagen a1 (Col2a...

ba0005p49 | Bone development/growth and fracture repair | ECTS2016

The effects of combined teriparatide and denosumab on bone regeneration

Kitaguchi Kazuma , Kashii Masafumi , Sugiura Tsuyoshi , Tokimitsu Morimoto , Noguchi Takaaki , Makino Takahiro , Ebina Kosuke , Kaito Takashi , Yoshikawa Hideki

Objective: The purpose of this study is to investigate the effects of the combined teriparatide (TPTD) and denosumab (DMAB) on both cortical and cancellous bone regeneration.Materials and methods: Bone defects were created in the diaphysis of the right femur and in the epimetaphysis of the left femur in 8-week old female C57/BL6N mice. After making bone defects, Mice were given either saline or 40 μg/kg TPTD for 20 days (5× per week) and were s...